EPAM Systems continues to solidify its place in the financial and technology markets. Recent upgrades from
Goldman Sachs saw an increase of the target price for EPAM shares and the company continues to receive a moderate to high buy rating from brokerages. Major strategic acquisitions including
First Derivative and
NEORIS have expanded the company's global financial services capabilities and AI-driven data solutions. Sophisticated product developments like
HealthOmics Platform on AWS and other composable services, demonstrate commitment to
AI-driven growth and digital transformation. EPAM's Q3 2024 earnings report surpassed expectations while company's forecast was revised upwards. The company's strategic expansion in
India and acquisition of
Vates broadens its geographical sphere. Recent recognitions by Gartner and IDC MarketScape further underline EPAM's leadership position in software development and data modernization services. While the company's stock performance has had some downturns, overall long-term growth view remains optimistic.
Growth in GCCs through modern engineering and scalability combined with robust hiring strategies shows EPAM's growth potential.
CloudFrame's Intelligent COBOL Transformation Platform investment highlights the company's versatile portfolio.
Epam Systems EPAM News Analytics from Wed, 28 Feb 2024 08:00:00 GMT to Fri, 06 Dec 2024 15:08:22 GMT -
Rating 7
- Innovation 8
- Information 7
- Rumor 5
